Access cutting-edge b-cell non-hodgkin's lymphoma treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.
Access b-cell non-hodgkin's lymphoma specialists in Nashville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related b-cell non-hodgkin's lymphoma treatment provided free
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa
Sponsor: Hoffmann-La Roche
Check if you qualify for this b-cell non-hodgkin's lymphoma clinical trial in Nashville, TN
If you're searching for b-cell non-hodgkin's lymphoma treatment options in Nashville, TN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b-cell non-hodgkin's lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.